title: Glucose metabolism and neurological outcome in congenital hyperinsulinism.
abstract: Advances in imaging and surgical techniques allow a complete cure for children with focal-type congenital hyperinsulinism (CHI). In contrast, management of diffuse-type CHI remains a matter of controversy. To prevent hypoglycemic brain damage, extensive surgery has been recommended in the past, resulting in diabetes. On the basis of 2 data sets of patients with congenital hyperinsulinism, the German registry for CHI with 235 patients (ages 1 day to 19 years) and the diabetes treatment register (Diabetes Patienten-Verlaufsdokumentationssystem initiative), a follow-up study was initiated for diabetes mellitus and the intellectual and physical development as well as motor function. In our ongoing study, we investigated 20 patients with CHI (12 male, mean ages 9.9 years). Six of 20 patients had undergone subtotal pancreatectomy. In early infantile development (0-3 years) we observed a trend to motor and speech delay. In early childhood (2.5-7 years) there appeared a trend to an advantage of results of nonverbal tasks compared with verbal tasks. Before 1990 most patients (∼75%) were treated by subtotal pancreatectomy; since 2000, a more conservative approach is obvious (4/68). All patients with diabetes (n = 25) developed the condition after undergoing subtotal pancreatectomy. No spontaneous manifestation of diabetes was noted before adulthood. There was a wide range of age (0-17.7 years) at manifestation indicating a long period during which glucose tolerance is compensated. Compared with >40.000 children with type 1 diabetes mellitus from the Diabetes Patienten-Verlaufsdokumentationssystem registry, we found significant differences with a tendency for being overweight as well as small stature. Mean daily insulin dose and HbA1c was comparable in both groups.
authors.affiliation: Department of Pediatrics, O. v. Guericke University, Magdeburg, Germany. anja.ludwig@med.ovgu.de
authors.forename: Anja
authors.initials: A
authors.lastname: Ludwig
authors.forename: Katja
authors.initials: K
authors.lastname: Ziegenhorn
authors.forename: Susann
authors.initials: S
authors.lastname: Empting
authors.forename: Thomas
authors.initials: T
authors.lastname: Meissner
authors.forename: Jan
authors.initials: J
authors.lastname: Marquard
authors.forename: Reinhard
authors.initials: R
authors.lastname: Holl
authors.forename: Klaus
authors.initials: K
authors.lastname: Mohnike
mesh_terms: D000293:Adolescent; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D044903:Congenital Hyperinsulinism / Q000453:epidemiology* / Q000628:therapy*; D002658:Developmental Disabilities / Q000453:epidemiology* / Q000209:etiology; D003920:Diabetes Mellitus / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D005858:Germany / Q000453:epidemiology; D005934:Glucagon / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007805:Language Development Disorders / Q000453:epidemiology* / Q000209:etiology; D008297:Male; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use; D010180:Pancreatectomy / Q000009:adverse effects; D011446:Prospective Studies; D011596:Psychomotor Disorders / Q000453:epidemiology* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D005934:Glucagon; D015282:Octreotide